Source Citation
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. https://pubmed.ncbi.nlm.nih.gov/21870978
Clinical Impact Ratings
GIM/FP/GP: 
Cardiology: 
Hematology:
Neurology:
References
- 1 Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. [PMID:
19717844 ] Google Scholar - 2 del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med. 2011;365:952-3. [PMID:
21830960 ] Google Scholar - 3 Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9. [PMID:
21900088 ] Google Scholar
Author, Article and Disclosure Information
Affiliations:
University of California San Francisco, San Francisco, California, USA (L.K.)
This article was published at Annals.org on 3 January 2012.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.